2022 EPCIS Implementation Benchmarking Survey

Published 2022

HDA, in collaboration with Vantage Solutions, is conducting quarterly surveys to assess the healthcare supply chain’s progress toward implementing GS1 Electronic Product Code Information Services (EPCIS), as well as trading partner plans for exchanging data, to comply with the Drug Supply Chain Security Act (DSCSA).

The DSCSA requires transaction data with product identifiers to be provided with physical product on November 27, 2023.The FDA has recommended that trading partners use the EPCIS standard to provide and maintain the data associated with transaction information and transaction statements. This survey informs industry trading partners on the status of successful data connections, defined as “a connection that is fully integrated and working in a production environment,” and perceived obstacles to implementation. Data reflect responses from across the pharmaceutical supply chain, including manufacturers, distributors and 3PLs.

This executive summary is a follow-up to the 2021 EPCIS Implementation Benchmarking surveys (Spring 2021 and Fall 2021) conducted by the HDA Research Foundation.

EPCIS 2022 Survey